Stanford researchers have developed a mouth-cooling device that prevents or reduces the degree of oral mucositis (OM), a painful side effect of chemotherapy, radiotherapy, autoimmune conditions, and infections.
Stanford scientists have discovered that Guanidinylated Serinol Charge-altering Releasable Transporters (GSer-CARTs) can be tuned for selective mRNA delivery to the lung and spleen in a predictable fashion.
The Stanford team developed a versatile injectable alginate-collagen hydrogel, a significant advancement in regenerative medicine and targeted therapeutic delivery.
Stanford scientists have discovered a DNA methylation signature on circulating tumor DNA (ctDNA) that can distinguish between the aggressive Leiomyosarcoma (LMS) from its benign counterpart leiomyoma (LM) in the uterus.
Researchers at Stanford have developed a novel T cell engineering platform that leverages constitutively active interleukin-9 receptor (IL-9R) signaling to improve the efficacy and scalability of immunotherapies for solid tumors.
Stanford scientists have developed a new DNA-based technology that allows therapeutic genes to be maintained in human cells for extended periods without altering the cell's chromosomes.
Researchers at Stanford have developed an innovative, non-invasive thermal treatment to recover the lost capacity of used lithium-ion batteries (LIBs), offering a scalable and cost-effective solution to the environmental challenges posed by battery waste.
Stanford researchers developed and patented a multiplexed immunohistochemistry method called multiplexed ion beam imaging (MIBI), which uses antibodies tagged with non-biological elemental isotopes (e.g. rare earth elements) and secondary ion mass spectroscopy.
Stanford scientists have developed fully human CD19-targeted CAR T cells designed to overcome the limitations of current CAR T cell therapies, particularly in treating low CD19 density blood cancers.
Stanford researchers have developed a novel, multi-specific chimeric antigen receptor (CAR) T-cell therapy designed to overcome the key challenges of treating solid tumors, including tumor heterogeneity, immune evasion, and CAR T-cell exhaustion.
Researchers at Stanford have developed an innovative molecular engineering strategy to enhance the stability and performance of polymer semiconductors (PSCs).
Stanford scientists have discovered that a specific protein signaling pathway can promote regenerative wound healing by suppressing fibrosis-related mechanosignaling.
Stanford researchers have developed a highly effective B7-H3 chimeric antigen receptor (CAR) for CAR-T cell therapy, designed to enhance binding and cytotoxicity against B7-H3 expressing solid tumors, offering a promising treatment for various cancers.